IL-17

cancer search news magnify

No Increase Malignancy Risk with Ixekizumab

Jack Cush, MD

A pooled analysis of 25 randomized clinical trials affirms the safety of ixekizumab (IXE) when used to treat patients with psoriasis (PsO), psoriatic arthritis (PsA), or axial spondyloarthritis (axSpA). The observed incidences of malignant neoplasms were consistent with the US general

Read Article
Biologic experienced ankylosing spondylitis patient show better retention on TNF compared to IL-17 inhibitors. 148 AS pts (F/U 31 mos), IL-17i drug survival trended better but only signif after 3yrs. More D/C w/ higher BASDAI (HR: 1.3) & ^# prior biologics (HR 1.62) https://t.co/5HXGsV4xol
Dr. John Cush @RheumNow( View Tweet )
38420215_s.jpg

Cancer Survival Outcomes in Autoimmune Skin Disease Patients

Jack Cush, MD

Patients with autoimmune skin diseases (ASDs) with cancer had significantly better cancer survival outcomes than those without ASD, suggesting coexistant autoimmune or inflammatory disease does not adversely affect a cancer prognosis.

Read Article
psoriatic.PIP_.JPG

Early DMARD Initiation Benefits in Psoriatic Arthritis

Jack Cush, MD

Mease et al has published the results of a cohort study showing early initiation of disease-modifying antirheumatic drugs (DMARDs) in patients with psoriatic arthritis (PsA) resulted in better outcomes compared to late initiation.

Read Article
PMR,flag

ICYMI: Secukinumab promise in PMR is real

David Liew, FRACP

Choice is not just good, it is often necessary, and secukinumab promises just that in both PMR and GCA.

Read Article
New IL-17 Inhibition New Molecular Constructs Dr. Philip Mease offers his perspective from the 2025 EULAR meeting in Barcelona, Spain. https://t.co/zz4NRITsRN https://t.co/FrUbmsjxxB

Links:

Dr. John Cush @RheumNow( View Tweet )
PSA2L.jpg

ICYMI: Combination treatments in Psoriatic Arthritis

Antoni Chan, MD, PhD

Despite the advances in the treatment of PsA with biologic (bDMARD) and targeted synthetic (tsDMARD), less than half of patients with this condition achieved remission or low disease activity. Combination DMARD treatment is often used in order to achieve remission or minimal disease activity.

Read Article
LBP_0.jpg

ICYMI: Axial Involvement in Psoriatic Arthritis

Jack Cush, MD

Analysis of a Greek Psoriatic Arthritis (PsA) cohort shows that nearly one quarter of patients have axial involvement, and among them, ∼30% have isolated spinal axPsA and nr-axSpA, respectively.

Read Article
IL-17 inhibitors - Long-term Extensions and Uveitis Dr. Peter Nash offers his perspective on data presented at the 2025 EULAR meeting in Barcelona. https://t.co/eQd0TcQn76 https://t.co/6Zog4LC8Aj

Links:

Dr. John Cush @RheumNow( View Tweet )
RheumNow Podcast square

PCR: Prevalence, Cost, & Risk (6.27.2025)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports from last week on RheumNow.com

Read Article
SI AS SpA ACR

Remission in Axial Spondyloarthritis Unrelated to Gut Inflammation

MedPage Today

Most patients with early, active axial spondyloarthritis (axSpA) who quickly received a tumor necrosis factor (TNF) inhibitor experienced remission, and it didn't matter whether or not they had intestinal inflammation at baseline, a small single-arm study found.

Read Article
Secukinumab & Uveitis = Unclear? Post hoc study of 11 SEC RCTs finds lower uveitis risk in AxSpA (N 1980; SEC 150 1.29/100PYs vs 1.72/100PY in PBO), but not in PsA (N 2453; SEC 300 0.71/100PY vs  zero w/ placebo) https://t.co/Gv9HheBU7l https://t.co/SlnrLRwmmn

Links:

Dr. John Cush @RheumNow( View Tweet )
Expanding the IL-17 Therapeutic Landscape IL-17 inhibitors are an effective therapeutic for a broad spectrum of inflammatory and autoimmune diseases and its blockade has revolutionized management of diseases such as psoriasis, psoriatic arthritis and SpA. https://t.co/Q7Thp1HJAL
Dr. John Cush @RheumNow( View Tweet )
Putting IL17i into ‘focus’ for SpA-associated uveitis The longest studied drug for uveitis in SpA has been monocolonal TNFi Abs. Reductions of acute anterior uveitis have been found with etanercept but less impressively than adalimumab, infliximab, and in my opinion less than https://t.co/AUEct0FxmU
Dr. John Cush @RheumNow( View Tweet )
Sonelokimab in PsA Dr. Adela Castro reports on OP0096, 'Impact of sonelokimab, a novel IL-17A- and IL-17F-inhibiting Nanobody, on multidomain clinical outcomes in active psoriatic arthritis: results from the randomized, double-blind, placebo-controlled Phase 2 ARGO trial,' https://t.co/KmV6Rx4uFT
Dr. John Cush @RheumNow( View Tweet )
PsA.Hands_.jpg

From Domains to Decisions: Personalizing PsA Care with Data

Jiha Lee, MD

At EULAR 2025, Dr. Laura Coates (Oxford) took the plenary stage to reframe how we think about treating psoriatic arthritis. The message was clear: in 2025, PsA treatment is no longer about following a linear algorithm; it’s about understanding the unique constellation of domains, comorbidities,

Read Article
Efficacy and Safety of Xeligekimab in AS Dr. Adela Castro reports on abstract OP0102 at the EULAR 2025 meeting in Barcelona, Spain https://t.co/xpzeV0oZOr https://t.co/mEYnAFsYQI

Links:

Dr. John Cush @RheumNow( View Tweet )
Impact of TNFi on efficacy of Vunakizumab in AS. -Post hoc analysis of Vunakizumab (humanized monoclonal IgG1/k antibody targeting IL-17A) trial on AS pts. -440 total pts, 163 had prior TNFi exposure - At week 16, no significant differences in ASAS20 b/w TNFi exposed pts https://t.co/O9PFOuLa5l

Links:

Adela Castro @AdelaCastro222( View Tweet )
Biologic switching in PsA: -Retrospective study on 3,851 PsA pts initiating bDMARDs, 1,848 (48%) switched therapy at least once. -TNFis were the initial therapy. -IL17i were the first switch in both single-switch and multi-switch scenarios. -Subsequent switches: back to TNFi https://t.co/tJDJvPeu9T

Links:

Adela Castro @AdelaCastro222( View Tweet )
Data from COAST-V study (post hoc) 🔹️Ixekizumab in #axSpA 🔹️Efficacy stratified by CRP level 🔹️Better treatment response in the elevated compared to the normal CRP group OP0699 #EULAR2025 @RheumNow https://t.co/1mVoly3Gws

Links:

Nelly ZIADE 🍀 @Nellziade( View Tweet )
🫁 In autoimmune ILD patients from FIBRONEER-ILD (n=325), nerandomilast slowed FVC decline vs placebo and reduced risk of ILD progression events (HR 0.56 for 18 mg BID). Acceptable safety profile & tolerability. @RheumNow #EULAR2025 #LB0003 https://t.co/aWsfNOL76n

Links:

Mrinalini Dey @DrMiniDey( View Tweet )
Guselkumab in APEX study (PsA, n=1020, biologic-naïve): 🦴 Less joint damage: 0.55 vs 1.35 (placebo) 💪 More responders: 67–68% hit ACR20 on GUS 🛡 Safety: similar to placebo GUS - selective IL-23i - delivers joint protection and symptom relief LB0010 @RheumNow #EULAR2025

Jiha Lee @JihaRheum( View Tweet )

APEX study Ph3 RCT Guselkumab In BioNaive active PsA w/ erosions>=2 wk 24 ACR20 GUS Q4W 67% Q8W 68% vs PBO 47% Less Rx progression in both Q4W & Q8W vs. PBO #EULAR2025 @RheumNow LB0010 https://t.co/OVDWWECtOZ

Links:

Aurelie Najm @AurelieRheumo( View Tweet )
Hidradenitis suppurativa is newer to us in rheumatology, but it seems like inflamm arthritis is a problem - at least to a similar extent as in psoriasis. Time for us to look for it & to see what therapies like IL-17 inhibitors do for this arthritis #EULAR2025 POS1237 @RheumNow https://t.co/b5EQdDEAhq

Links:

David Liew @drdavidliew( View Tweet )
👁️Uveitis in axSpA: -Up to 40% can present before SpA dx -NMA of 44 RCTs showed tx with TNFi, JAKi and IL-17i protective effects against uveitis -Low rates of uveitis in axSpA pts on BIME trials suggests its possible beneficial effects. #EULAR2025 @RheumNow https://t.co/mPuSMnD1Zs

Links:

Adela Castro @AdelaCastro222( View Tweet )

Recent Blogs

Best of 2022: The Enthesitis Challenge in Psoriatic Arthritis

Robert Chao, MD
heel enthesitis spur calcaneal
A colleague of mine once told me an interesting story of how her father, who was a doctor, misdiagnosed his wife with fibromyalgia when she actually had psoriatic arthritis with enthesitis all along. I would venture out and say that the average physician would have trouble evaluating enthesitis because even we, as rheumatologists do!  Read Post

Best of 2022: Toss of a Coin - How do You Choose PsA Medication?

M. Elaine Husni, MD, MPH
Coin toss
When balancing all these disease domains, individual phenotypes, and comorbidities, sometimes treatment decisions can feel like tossing a coin. Fortunately, numerous guidelines have been published to help us do better than tossing a coin…or do they?  Read Post
×